Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study: American Journal of Hematology

F. Morabito, G. Tripepi, G. Del Poeta, F.R. Mauro, G. Reda, P. Sportoletti, L. Laurenti, M. Coscia, Y. Herishanu, M. Varettoni, R. Murru, A. Chiarenza, A. Visentin, A. Condoluci, R. Moia, D. Pietrasanta, G. Loseto, U. Consoli, I. Scortechini, F.M. RossiA. Zucchetto, E. Vigna, E.A. Martino, F. Mendicino, C. Botta, D. Caracciolo, R. Cassin, G. D'Arrigo, S. Galimberti, A. Rago, I. Angeletti, A. Biagi, I. Del Giudice, R. Bomben, A. Neri, G. Fronza, G. Cutrona, D. Rossi, F. Di Raimondo, A. Cuneo, G. Gaidano, A. Polliack, L. Trentin, R. Foà, M. Ferrarini, V. Gattei, M. Gentile

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)E168-E171
JournalAm. J. Hematol.
Volume96
Issue number5
DOIs
Publication statusPublished - 2021

Keywords

  • adenine
  • antineoplastic agent
  • ibrutinib
  • piperidine derivative
  • protein kinase inhibitor
  • aged
  • chronic lymphatic leukemia
  • female
  • follow up
  • human
  • information processing
  • male
  • middle aged
  • mortality
  • multicenter study (topic)
  • prognosis
  • proportional hazards model
  • reproducibility
  • retrospective study
  • risk assessment
  • severity of illness index
  • survival analysis
  • Adenine
  • Aged
  • Antineoplastic Agents
  • Datasets as Topic
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Piperidines
  • Prognosis
  • Progression-Free Survival
  • Proportional Hazards Models
  • Protein Kinase Inhibitors
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis

Cite this